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Edited by Angel NedredaAbstract Considerable evidence supports the view that D-type
cyclins play a role in G1-S progression. We found that cyclin
D2 directly interacts with Mel-18, one of the polycomb group
gene products in a yeast two hybrid screen. Further, we have
determined the binding domains that are required for interaction
between cyclin D2 and Mel-18. The proline/serine-rich domain
(P/S domain) of Mel-18 is required to interact with cyclin D2,
and the N-terminal region of cyclin D2 is necessary to interact
with Mel-18. A co-localization study shows that cyclin D2 and
Mel-18 interact within the nucleus. To determine whether Mel-
18 aﬀects cyclin D2 activity, we blocked Mel-18 expression using
an anti-sense strand system in cyclin D2 over-expressing cells.
The results indicate that cells with reduced Mel-18 expression
levels show more proliferative activity than the controls. These
ﬁndings are the ﬁrst report that Mel-18 directly interacts with
cyclin D2 and may inhibit cyclin D2 activity.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The cell cycle is governed by two main events. One is an
interphase, in which cell growth and DNA replication occur.
The other is a mitotic phase, in which cell division occurs.
During these events, the ‘‘restriction point’’ in the G1 phase
is critical for determining whether or not the cell commits to
replicate the genome and undergo cell division [1]. The proper
control of ‘‘restriction point’’ progression is important for
maintaining normal levels of cell growth and proliferation
because the cell cycle cannot stop or go back after the cell cycle
passes through the ‘‘restriction point’’ [2].Abbreviations: cdk, cyclin-dependent kinase; CHO, Chinese hamster
ovary; HTH, helix-turn-helix; MTT, 3-(4,5-dimethylthiazol-2-yl)-2.5-
diphenyl-2H-tetrazolium bromide; P/S domain, proline/serine-rich
domain; PcG, polycomb group; pRb, retinoblastoma tumor suppres-
sor gene product
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doi:10.1016/j.febslet.2005.08.050Much evidence indicates that cell cycle progression through
the ‘‘restriction point’’ is controlled by the retinoblastoma
tumor suppressor gene product (pRb), and by the related pro-
teins p107 and p130 [3]. The pRb inhibits the transcription of
several genes whose products are necessary to transit from the
‘‘restriction point’’ to S phase [3]. The activity of pRb is also
inhibited by a sequential phosphorylation from cyclin-depen-
dent kinases (cdks) associated with D-type cyclins in the G1
phase [4,5].
The D-type cyclins play a critical role in controlling initial
cell cycling. When one of the D-type cyclins activates cdks,
one of cdks phosphorylates pRb. After that, the cell cycle
passes from the G1 phase to S phase. When cells receive the
growth signals, they express at least one of the D-type cyclins
from among cyclin D1, cyclin D2, and cyclin D3 [6]. Although
many diﬀerent growth stimuli initiate cell proliferation
through a speciﬁc signaling pathway, the activation of one of
the D-type cyclins is absolutely required for entering S phase
in non-cancerous cells [7]. Thus, the expression proﬁle of
D-type cyclins can be represented as the gold standard of cell
cycle entry.
Cyclin D2 was initially identiﬁed as the essential mediator
for mature B cell proliferation. By binding cdks, they make a
cell cycle enter S-phase in mature B cells [8,9]. However, mice
bearing a disrupted cyclin D2 gene show only limited-tissue-
speciﬁc abnormalities, such as testes and ovaries [10]. This
may indicate that each cyclin D is expressed in an overlapping,
apparently redundant fashion in the proliferating cells.
Compared to cyclin D1 and cyclin D3, the regulating mech-
anism of cyclin D2 activity remains unknown. In particular,
not many proteins have been identiﬁed to interact with cyclin
D2, except cdks. The identiﬁcation of proteins that interact
with cyclin D2 may be the ﬁrst step in deﬁning the regulating
mechanism of cyclin D2 activity. As an initial step to deﬁne the
regulating mechanism of cyclin D2 activity, we used a yeast
two-hybrid system to screen a human spleen cDNA library
for a novel cyclin D2 binding protein.2. Materials and methods
2.1. Yeast two-hybrid screening
For bait construction with human cyclin D2, cDNA encoding
full-length human cyclin D2 was subcloned into the EcoRI and SalI
restriction sites of pGilda. The resulting plasmid pGilda-cyclin D2
was introduced into yeast strain EGY48 [MATa, his3, trp1, ura3-52,blished by Elsevier B.V. All rights reserved.
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ﬁed lithium acetate method [11]. The human spleen cDNA library
was constructed by cloning cDNA fragments into the EcoRI and XhoI
restriction sites of pJG4-5 to generate B42 fusion proteins (Clontech,
Palo Alto, USA). The cDNAs encoding B42 fusion proteins were then
introduced into the competent yeast cells that already contained pGilda-
cyclin D2, and the transformants were selected for the tryptophan pro-
totrophy (plasmid marker) on synthetic medium (Ura, His, Trp)
containing 2% glucose. Pools of 4 · 106 independent cDNA clones
from the human spleen cDNA library were screened.
2.2. Quantitation of interaction between cyclin D2 and Mel-18
Two deletion mutants (D155–289 and D1–154) of cyclin D2 were iso-
lated by polymerase chain reaction (PCR). PCR products spanning
each fragment were cloned into the EcoRI and XhoI restriction sites
of the pGilda. Four deletion mutants (D57–344, D203–334, D230–344
and D1–229) of Mel-18 were also isolated by PCR. PCR products
spanning each fragment were cloned into the EcoRI and XhoI restric-
tion sites of the pJG4-5. Each constructed plasmid was introduced into
yeast EGY48 expressing either the cyclin D2 or Mel-18 hybrid protein.
The binding strength between cyclin D2 and Mel-18 was determined
quantitatively by the relative expression level of b-galactosidase. The
b-galactosidase assay was performed according to the previously
described method [12] with slight modiﬁcation. Brieﬂy, yeast cells
(EGY48 strain) containing each construct were cultured in yeast syn-
thetic media (Ura, His, Trp) with 2% glucose until they reached
mid-log phase. Next, the cells were transferred in a yeast medium
(Ura, His, Trp) containing 2% galactose and 0.2% Me2SO. Equiv-
alent numbers of cells were lyzed in 0.7 ml Z buﬀer (60 mM Na2HPO4,
40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, and 50 mM b-mercap-
toethanol, pH 7.0) containing 50 ll of 0.1% SDS and 50 ll of chloro-
form for 30 s at 30 C. Then, b-galactosidase activity was measured by
adding 140 ll of 4 mg/ml o-nitrophenyl b-D-galactopyranoside
(ONPG). The reaction was carried out at 30 C until yellow color
appeared, and then quenched by adding 0.4 ml of 1 M Na2CO3. The
samples were centrifuged brieﬂy to remove cell debris, and the
supernatant absorbance was measured at 420 and 550 nm. The b-gala-
ctosidase activity was calculated using the formula, units = [1000 ·
(A4201.75 · A550)]/(time · volume · A600).2.3. Co-immunoprecipitation
The cDNA encoding human cyclin D2 was isolated by PCR and
then cloned into pEGFPC1 (Clontech) (pEGFPC1-cyclin D2). The
cDNA encoding human Mel-18 was isolated by PCR and ligated into
pcDNA4/HisMax (Invitrogen Life Technologies, Carlsbad, USA)
(pcDNA4/HisMax-Mel-18). For co-immunoprecipitation, Chinese
hamster ovary (CHO) cells were co-transfected with cDNA constructs
of pEGFPC1-cyclin D2 and an empty pcDNA4/HisMax (vector only),
an empty pEGFPC1 (vector only) and pcDNA4/HisMax-Mel-18, or
pEGFPC1-cyclin D2 and pcDNA4/HisMax-Mel-18 using FuGENE6
(Roche Applied Science, Basel, Switzerland). Three days after transfec-
tion, cells were harvested by trypsinization and centrifugation. Cell
pellets were washed in PBS, resuspended in cell lysis solution
(50 mM Tris, pH 7.2, 150 mMNaCl, 1% Triton X-100, 1 lg/ml leupep-
tin, 1 lg/ml pepstatin, 2 lg/ml aprotinin, 200 lg/ml PMSF). Lysates
were incubated with anti-GFP antibody (Invitrogen Life Technologies;
cat # A-6455) and precipitated with protein A-agarose. The precipi-
tated proteins were resolved by SDS gel electrophoresis, transferred
onto Immobilon P membrane (Millipore Corporation, Billerica, Mas-
sachusetts, USA), and immunoblotted with anti-His antibody (GE
Healthcare, Piscataway, New Jersey, USA; cat # 27-4710-01), rabbit
anti-cyclin D2 antibody (Santa Cruz Biotechnology, Santa Cruz,
Calif., USA; cat # sc-181) or using the ECL system (GE Healthcare).2.4. Co-localization
The cDNA encoding human cyclin D2 was isolated by PCR and
then cloned into pEGFPC1 (Clontech). The human Mel-18 cDNA
was isolated by PCR and ligated into the pRc vector (Invitrogen Life
Technologies). For co-localization, CHO cells were grown in DMEM
and co-transfected with both cyclin D2-GFP and Mel-18 cDNAs.
Three days after transfection, cells were harvested, ﬁxed with 1% para-
formaldehyde and permeabilized in 0.15% saponin. After ﬁxation of
cells, rabbit anti-Mel-18 antibody (Santa Cruz Biotechnology; cat #H-115) coupled with PE-anti-rabbit immunoglobulin (Sigma, St.
Louis, USA) was stained. After staining, DAPI was added to visualize
nucleus and characterized in ﬂuorescence microscope (Nikon, Japan).
2.5. Inhibition of Mel-18 in cyclin D2 over-expressing cells measured by
proliferation assay
T47D breast cancer cells were transfected with expression vectors
containing vector only (mock), anti-sense strand of Mel-18 cDNA
only, cyclin D2 cDNA only or Cyclin D2 and anti-sense strand of
Mel-18 cDNAs. For preparing anti-sense Mel-18 cDNA, the open
reading frame encoding human Mel-18 cDNA was reversely cloned
into the pRc vector. T47D breast cancer cells transfected with each
cDNA were seeded at a density of 1 · 103 cells/well in 96-well plates.
One, three and ﬁve days after transfection, fresh medium containing
10% FBS, 20 ll of 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl-2H-tetra-
zolium bromide (MTT) solution (Sigma, 5 lg/ml) was added to each
well. Each well was incubated for an additional 4 h at 37 C. The
amount of MTT-formazan was determined by absorbance at
540 nm. Absorbance of each sample was converted into the relative
rate of cell growth.3. Results
3.1. Identiﬁcation of Mel-18 as a cyclin D2 binding protein
The human spleen cDNA library fused to the gene for the
transcription activator pJG4-5 was introduced into yeast cells
containing the pGilda-cyclin D2 as bait. Approximately
4 · 106 independent transformants were pooled and respre-
aded on the selection media (Ura, His, Trp, Leu) contain-
ing 2% galactose to induce the expression of cDNA. If a B42
tagged protein interacts with the cyclin D2, it will activate
the transcription of LEU2 gene and allow the host cells to
grow on a synthetic medium lacking leucine. Among ﬁve colo-
nies obtained on the selection media, a total of four positive
yeast colonies showed galactose dependency. The plasmids
were isolated from the selected yeast cells and introduced into
Escherichia coli KC8 to isolate the plasmids carrying pJG4-5
cDNA inserts. The plasmids were then isolated by the plasmid
marker trp in the E. coli host, and the puriﬁed plasmids were
sequenced. An homology search in GenBank using the BLAST
program revealed that all plasmids encoded human Mel-18.
All of the Mel-18 encoded plasmids contained a cDNA with
100% identity to the 210 amino acid C-terminal sequence of
human Mel-18 (GenBank accession number: BC004858;
Ile135-Thr344; Fig. 1A).
The interaction between cyclin D2 and Mel-18 was further
examined by the yeast two hybrid system and co-immunopre-
cipitation. In the two-hybrid system, the full-length human
cyclin D2 cDNA and either empty plasmid or plasmid contain-
ing a full-length human Mel-18 cDNA were co-transformed
into EGY48 yeast cells. Cells containing only full-length
Mel-18 cDNA construct grew on the Ura, His, Trp and Leu
deﬁcient plates, whereas yeast cells transformed with an empty
plasmid failed to grow (data not shown). To conﬁrm this
result, we determined the binding strength of these constructs
by measuring the relative expression level of b-galactosidase.
The b-galactosidase activity for an interaction between cyclin
D2 and Mel-18 was fully observed, whereas very little b-galac-
tosidase activity was observed between cyclin D2 and the
empty vector (b-galactosidase activity of cyclin D2 and empty
vector: 0.56 ± 0.35 vs. b-galactosidase activity of cyclin D2 and
Mel-18: 90.24 ± 3.74; data not shown). For co-immunoprecip-
itation, cDNA constructs of pEGFPC1-cyclin D2 and an
empty pcDNA4/HisMax (vector only), an empty pEGFPC1
Fig. 1. Interaction of Mel-18 with cyclin D2. (A) The amino acid sequence of Mel-18 is indicated using single letter abbreviations. An underlined
amino acid sequence means the translated Mel-18 protein was isolated from yeast two-hybrid screening. (B) Co-immunoprecipitation of Mel-18 with
cyclin D2. Lane 1; lysate from pEGFPC1-cyclin D2 and pcDNA4/HisMax (vector only) co-transfectant, lane 2; lysate from pEGFPC1 (vector only)
and pcDNA4/HisMax-Mel-18 co-transfectant, lane 3; lysate from pEGFPC1-cyclin D2 and pcDNA4/HisMax-Mel-18 co-transfectant. IP means
immunoprecipitation and WB means immunoblotting with indicated antibodies.
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cyclin D2 and pcDNA4/HisMax-Mel-18 were co-transfected
into CHO cells. Subsequently, an immunoprecipitation was per-
formed using anti-GFP antibody with lysates from transfected
cells. After immunoprecipitation, the precipitated proteins
were immunoblotted using anti-His antibody or anti-cyclin
D2 antibody. As shown in Fig. 1B, Mel-18 was co-immunopre-
cipitated with cyclin D2 (lane 3 in upper panel), whereas no
interaction was observed between cyclin D2 and an empty vec-
tor (lane 1 in upper panel) or Mel-18 and an empty vector (lane
2 in upper panel). An immunoblot using anti-cyclin D2 anti-
body conﬁrmed that an equal amount of cyclin D2 was precip-
itated in lanes 1 and 3 (middle panel). Whole cell lysates from
both samples contained the equivalent proteins when we
immunoblotted using anti b-actin antibody (lower panel).
3.2. Mapping of the interaction region between human cyclin D2
and human Mel-18
A recent study indicated that three major domains were
located within Mel-18 [13]. The N-terminal region contains a
RING-ﬁnger domain and two a-helix of the putative helix-
turn-helix (HTH) domain in the middle of Mel-18 (upper panel
in Fig. 2A). The C-terminal region contains the proline-serine
(P/S) rich domain (upper panel in Fig. 2A). To identify the
cyclin D2 binding region of Mel-18, cDNA constructs contain-
ing three deletion mutants were designed (lower panel in
Fig. 2A).
In the two-hybrid system, the full-length human cyclin D2
cDNA and either a plasmid containing a full-length human
Mel-18 cDNA (full, lower panel in Fig. 2A) or plasmids con-taining three truncation mutant forms (D57–344, D203–334
and D230–344, lower panel in Fig. 2A) of cDNAs were co-
transformed into EGY48 yeast cells. Only cells containing
the full-length Mel-18 cDNA construct grew on the Ura,
His, Trp and Leu deﬁcient plates, whereas yeast cells trans-
formed with deletion mutant colonies (D57–344, D203–334
and D 230–344) failed to grow (Fig. 2B). To conﬁrm this result,
we determined the binding strength of these constructs by
measuring the relative expression level of b-galactosidase.
The liquid b-galactosidase assay results conﬁrmed that cyclin
D2 needs for binding the proline/serine-rich domain (P/S
domain) of Mel-18 (the values of b-galactosidase activity
(units) are indicated below the corresponding lanes in Fig. 2B).
Subsequently, a cDNA construct containing one cyclin D2
truncation mutant was designed to localize the Mel-18 binding
region of cyclin D2. As shown in the upper panel of Fig. 3A,
cyclin D2 was divided by two domains [14]. In the two-hybrid
system, full-length human Mel-18 cDNA and either full-length
human cyclin D2 cDNA (full, lower panel in Fig. 3A) or one
truncation mutant (D155–289, lower panel in Fig. 3A) were
co-transformed into EGY48 yeast cells. Cells containing
full-length cyclin D2 cDNA (full, Fig. 3A) and one truncation
mutant (D155-289) grew on the Ura, His, Trp and Leu deﬁ-
cient plates (Fig. 3B). We also quantitated the binding strength
of these constructs by measuring the relative expression level of
b-galactosidase. Consistent with Fig. 3B, the critical cyclin D2
region for binding Mel-18 resided within Met1 and Val154 (the
values of b-galactosidase activity (units) are indicated below
the corresponding lanes in Fig. 2B). Interestingly, the b-galac-
tosidase activity for interactions between Mel-18 and one
Fig. 2. Proline/serine-rich domain (P/S domain) of Mel-18 protein is
required for binding of cyclin D2. (A) Upper panel shows the
schematic representation of domain structures of Mel-18 and lower
panel shows the schematic representation of cDNA constructs for each
Mel-18 deletion mutant and full-length human Mel-18 fusion proteins
in the yeast two-hybrid system. (B) cDNA constructs were co-
transformed into EGY48 yeast cells to test a protein-protein interac-
tion within the yeast two-hybrid system. The values of b-galactosidase
activity (units) measured by ONPG assays are indicated below the
corresponding lanes. The values of b-galactosidase activity in negative
controls (vector only) of each construct were below 0.15 ± 0.04. The
results are representative of three separate experiments. Data are
shown as means ± S.E.
Fig. 3. Mapping of the cyclin D2 interaction region with Mel-18 using
the yeast two-hybrid system. (A) Upper panel shows the schematic
representation of domain structures of cyclin D2 and lower panel
shows the schematic representation of cDNA constructs for a cyclin
D2 deletion mutant and a full-length human cyclin D2 fusion protein
in the yeast two-hybrid system. (B) cDNA constructs were co-
transformed into EGY48 yeast cells to test a protein–protein interac-
tion within the yeast two-hybrid system. The values of b-galactosidase
activity (units) measured by ONPG assays are indicated below the
corresponding lanes. The values of b-galactosidase activity in negative
controls (vector only) of each construct were below 0.14 ± 0.02. The
results are representative of three separate experiments. Data are
shown as means ± S.E. (C) cDNA constructs for a Mel-18 deletion
mutant (D1-229) and two cyclin D2 deletion (D155–289 and D1–154)
fusion proteins in the yeast two-hybrid system. cDNA constructs were
co-transformed into EGY48 yeast cells to test a protein–protein
interaction within the yeast two-hybrid system. The values of
b-galactosidase activity (unit) measured by ONPG assays is indicated
below the corresponding lanes. The results are representative of three
separate experiments. Data are shown as means ± S.E.
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Mel-18 (full, Fig. 3A).
To conﬁrm these results, cDNA constructs containing one of
human Mel-18 deletion mutant (D1–229, Fig. 3C) and either a
C-terminal deletion mutant of human cyclin D2 (D155–289,
Fig. 3C) or N-terminal deletion mutant of human cyclin D2
cDNA (D1–154, Fig. 3C) were co-transformed into EGY48
yeast cells. Cells containing human the Mel-18 deletion mutant
(D1–229) and the C-terminal deletion mutant of human cyclin
D2 (D155–289) grew only on the Ura, His, Trp and Leu deﬁ-
cient plates (Fig. 3C). We also quantitated the binding strength
of these constructs by measuring the relative expression level of
b-galactosidase. Consistent with Fig. 3B, the critical binding
region between cyclin D2 and Mel-18 resided within the
proline/serine-rich domain (P/S domain) of Mel-18 and N-
terminal region (Met1 and Val154) of cyclin D2 (the values of
b-galactosidase activity (units) are indicated below the corre-
sponding lanes in Fig. 2C). This result may also indicate that
the region within the C-terminal region of cyclin D2 enhances
Mel-18 binding, but is not critical.
3.3. co-localization of cyclin D2 and Mel-18
To identify the exact cellular region in which cyclin D2 and
Mel-18 interact, we performed a co-localization assay by stain-
ing anti-Mel-18 antibody in cyclin D2-GFP and Mel-18 over-
expressing cells. Brieﬂy, CHO cells were grown in DMEM and
co-transfected with cyclin D2-GFP and/or Mel-18 cDNAs.
Three days after transfection, cells were harvested, stained with
anti-Mel-18 antibody conjugated with PE-anti-rabbit immuno-
globulin. After staining, DAPI was added to visualize the nu-cleus, then characterized using a ﬂuorescence microscope. As
shown in the third panel of Fig. 4, DAPI staining was matched
with the expression pattern of cyclin D2 and Mel-18. Cells
transfected with an empty vector were only stained by DAPI
(the ﬁrst panel in Fig. 4). The expression of Mel-18 alone or
cyclin D2 alone was visualized in the nucleus (the second panel
in Fig. 4; data not shown). To test if Mel-18 expression inﬂu-
ences the pattern of cyclin D2 expression, we also co-transfec-
ted cDNA encoding cyclin D2-GFP and anti-sense Mel-18
cDNAs into CHO cells. As shown in the fourth panel of
Fig. 4, cyclin D2 was still localized within the nucleus. These
results indicate that both cyclin D2 and Mel-18 reside indepen-
dently and interact within the nucleus.
3.4. Mel-18 inhibits cyclin D2 activity
To determine whether Mel-18 aﬀects the activity of cyclin
D2, we tried to block Mel-18 expression in cyclin D2 over-
expressing cells by transfecting with anti-sense cDNA of
Mel-18. In mock transfection, the cyclin D2 expression was
Fig. 4. Co-localization of cyclin D2 and Mel-18 in the nucleus. CHO cells were grown in DMEM and co-transfected with both cyclin D2-GFP and
Mel-18 cDNAs. Cells expressing cyclin D2-GFP fusion protein and Mel-18 protein were ﬁxed, permeabilized and stained with anti-Mel-18 antibody
and DAPI. After staining, cells were examined in a ﬂuorescence microscope.
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tern blot analysis (lane 1, Fig. 5A). We observed both cyclin
D2 and Mel-18 proteins in T27D cells transfected with cyclin
D2 cDNA only (lane 3, Fig. 5A). In T27D cells transfected
with the anti-sense strand of Mel-18 cDNAs, we observed very
little Mel-18 proteins (lane 2 and lane 4, Fig. 5A). These results
clearly indicate that Mel-18 expression was blocked by trans-
fecting with the anti-sense cDNA of Mel-18.
Using these cells, we performed MTT assays to assess the
eﬀect of Mel-18 on cyclin D2 activity. As shown in Fig. 5B,
cells transfected with cyclin D2 cDNA only and anti-sense
Mel-18 cDNA only grow faster compared to a mock transfec-
tant. The growth rate of cells transfected with cyclin D2 cDNA
and anti-sense strand of Mel-18 cDNA was the highest among
those transfectants. These results demonstrate that Mel-18
inhibits cyclin D2 activity.4. Discussion
We identiﬁed Mel-18, one of the polycomb group gene pro-
ducts, as a novel cyclin D2 binding protein. The interaction
between cyclin D2 and Mel-18 could be the ﬁrst example of
a regulatory mechanism of cyclin D2 which has a role in the
cell cycle.
Biochemical analysis of Mel-18 revealed that there are three
functional domains of Mel-18 [13]. One is the RING domain
located in the N-terminal region between Cys18 and Cys56. In
the middle of Mel-18 between Lys158 and Val229, two a-helices
are located that make the HTH structure. The C-terminal
region of Mel-18 between Gln230 and Thr344 is proposed to
be a proline/serine-rich domain (P/S domain). Compared with
other mammalian polycomb group (PcG) protein, the RING
domain and HTH structure seem to be well conserved in mam-
malian PcG protein [13]. Also, the RING domain and HTH
structure are important for the dimerization of Mel-18 itself
[13]. Our results in the cyclin D2 binding assay with Mel-18,using a yeast two-hybrid system, revealed that the critical
Mel-18 region for binding cyclin D2 resided between Gln230
and Thr344, containing the proline/serine-rich domain (P/S
domain) of Mel-18.
To determine which cyclin D2 regions are required for the
interaction with Mel-18, we constructed one deletion mutant
and tested it using a yeast two-hybrid system. Results indicate
that the N-domain region of cyclin D2 is critical for binding
Mel-18. However, the C-terminal region of cyclin D2 may
enhance Mel-18 binding, since the binding strength of the
cyclin D2 N-domain alone is not enough to show full strength
binding with Mel-18.
The results in the co-localization assay indicate that both
cyclin D2 and Mel-18 reside and interact within the nucleus.
It has been shown that other mammalian PcG proteins, such
as Bmi-1 and M33, are localized in the nucleus [15,16], but this
is the ﬁrst report showing that Mel-18 is also localized in
nucleus.
A recent study indicated that Mel-18 functions as a tumor
suppressor that inhibits cell growth [17]. Blocking endoge-
nous mel-18 expression by anti-sense RNA in NIH 3T3 cells
accelerates cell cycling [17]. Also, most breast cancer cell
lines showed the decreased expression of mel-18 mRNA
[18]. However, how Mel-18 acts as a tumor suppressor is
not known.
In this study, we provide direct evidence that Mel-18 inhibits
the cell cycle via binding with cyclin D2, because the growth
rate of cells is increased by blocking Mel-18 activity in cyclin
D2 over-expressing cells. Thus, it is possible that Mel-18 binds
to cyclin D2 before one of the cdks binds with cyclin D2 in the
steady state. When growth stimuli are applied to the cell, the
conformational change between cyclin D2 and Mel-18 may
allow cyclin D2 to bind with one of the cdks instead of Mel-
18. It is interesting that blocking the expression of Mel-18 itself
induces cell proliferation. Thus, it is possible that Mel-18
regulates other D-type cyclins or components involved in the
cell cycle.
Fig. 5. Mel-18 inhibits cyclin D2 activities. T47D breast cancer cells
were transfected with a mock (an expression vector only without
insert), anti-sense strand of Mel-18 cDNAs, cyclin D2 cDNA only
(cyclin D2) or cyclin D2 and anti-sense strand of Mel-18 cDNAs. A.
The inhibition of Mel-18 expression by anti-sense strand. Western blot
analysis was performed to conﬁrm the inhibition of Mel-18 expression
by transfecting anti-sense strand of Mel-18 cDNAs. Lanes: 1, mock
transfectant (vector only); 2, anti-sense Mel-18 transfectant; 3, cyclin
D2 transfectant; 4; both cyclin D2 and anti-sense Mel-18 transfectant.
B. The rate of cell growth was quantiﬁed by MTT assays. The amount
of MTT-formazan was determined by absorbance at 540 nm. Absor-
bance of each sample was converted into the relative rate of
proliferation. The results are representative of three separate experi-
ments. Data are shown as means ± S.E.
5280 T. Chun et al. / FEBS Letters 579 (2005) 5275–5280In summary, we have identiﬁed Mel-18 as a novel binding
partner for cyclin D2 via yeast two-hybrid screening. We have
also mapped the critical molecular domains required for this
interaction and co-localized both proteins in the nucleus. Fi-
nally, transfection experiments indicate that Mel-18 may bind
cyclin D2 to prevent cell proliferation. These combined results
suggest that Mel-18 may have an important biological role in
regulating cyclin D2 function, and possibly may have a role
in anti-tumor therapy.Acknowledgments: This work was supported by a grant from the
Hanyang University research fund to Gu Kong (Grant No. HY-
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